206 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28085275	53	Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.	Bristol-Myers Squibb
10782685	9	Synthesis of a cyanopeptide-analogue with trypsin activating properties.	Ernst-Moritz-Arndt-University
28197309	40	Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.	Global Blood Therapeutics
27994741	48	Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.	Bristol-Myers Squibb R & D
27455395	66	Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.	Bristol-Myers Squibb R & D
27073051	71	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.	Bristol-Myers Squibb
26732532	69	Active site-directed plasmin inhibitors: Extension on the P2 residue.	Kobe Gakuin University
26421993	44	Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.	Aurigene Discovery Technologies
26393374	34	Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.	Queensland University of Technology
25592713	37	Pyridine and pyridinone-based factor XIa inhibitors.	Bristol-Myers Squibb
25987378	2	Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).	Kyoto Pharmaceutical University
25921265	21	Novel type of plasmin inhibitors: providing insight into P4 moiety and alternative scaffold to pyrrolopyrimidine.	Hiroshima International University
25782055	9	Discovery of a Cyclic Boronic Acidß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.	Rempex Pharmaceuticals
25728130	79	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.	Bristol-Myers Squibb
24900876	56	Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.	Astrazeneca
152812	69	Inhibition of four human serine proteases by substituted benzamidines.	TBA
660589	3	Inactivation of trypsin-like proteases by sulfonylation. Variation of positively charged group and inhibitor length.	TBA
24613052	69	Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.	Hiroshima International University
24405333	69	Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.	Bristol-Myers Squibb
24175584	35	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.	Sanofi-Aventis R&D
24135727	7	Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.	Emory University
23899618	9	Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.	Lg Life Sciences
23586812	38	Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy.	Ecole Polytechnique F�D�Rale De Lausanne Epfl
23521080	6	Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid.	Astrazeneca
23294255	114	Development of new cyclic plasmin inhibitors with excellent potency and selectivity.	Philipps University Marburg
16644215	52	Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.	Celera Genomics
16554154	9	Development of activity-based probes for trypsin-family serine proteases.	Celera Genomics
22882079	26	Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase.	Aarhus University
23124211	22	Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.	Zydus Research Centre
22950366	6	Thrombin inhibitors from the freshwater cyanobacterium Anabaena compacta.	Hokkaido University
22276953	63	A new strategy for the development of highly potent and selective plasmin inhibitors.	Philipps University Marburg
22366654	33	2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.	University of Louisville
19861238	14	Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one.	Takeda Pharmaceutical
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
15787457	3	Sesquiterpenoids and plasmin-inhibitory flavonoids from Blumea balsamifera.	Chiba University
18164204	24	Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors.	Takeda Pharmaceutical
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18077174	31	Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.	Takeda Pharmaceutical
18054227	45	Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.	Bristol-Myers Squibb Research and Development
18052026	97	Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.	University of Antwerp
17588746	103	SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.	Bristol-Myers Squibb
16517159	45	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety.	Abbott
16250649	10	Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.	Brown University
15887966	58	Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.	Central Pharmaceutical Research Institute
15582437	2	Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.	Central Pharmaceutical Research Institute
14640539	112	Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).	Pharmaceutical Research Institute
12904065	30	Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.	Lg Life Sciences
11170646	106	Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.	Dupont Pharmaceuticals
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
10579821	51	Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency.	Novartis Horsham Research Centre
10479288	141	Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.	Rh£Ne-Poulenc Rorer
9836616	92	Tetrahydro-isoquinoline-based factor Xa inhibitors.	Boehringer Mannheim
9083470	9	Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.	Merck Research Laboratories
9357536	47	Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.	Merck Research Laboratories
9301673	234	Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.	Klinikum Der Friedrich-Schiller-Universit£T Jena
2231595	96	Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.	Abbott Laboratories
12270173	23	Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones.	Universit£
10915051	43	The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.	Novartis Horsham Research Centre
	22	Design and synthesis of conformationally constrained arginal thrombin inhibitors	TBA
	48	DERIVATIVES OF 4-AMINO-PYRIDINE AS SELECTIVE THROMBIN INHIBITORS	TBA
22285569	107	Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).	University of Antwerp
22041058	44	Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.	Bristol-Myers Squibb
21944858	12	Identification of novel plasmin inhibitors possessing nitrile moiety as warhead.	Hiroshima International University
21741839	83	Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.	Philipps University Marburg
21168329	47	New furin inhibitors based on weakly basic amidinohydrazones.	Philipps University Marburg
20650636	118	Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate.	F. Hoffmann-La Roche
20405925	5	Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020.	University of Basel
20355714	26	Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.	Takeda Pharmaceutical
20102150	35	Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.	Johnson & Johnson Pharmaceutical Research and Development
20038105	50	Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics.	Philipps University Marburg
19703768	63	Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).	Berlex Biosciences
19541481	57	Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.	Bristol-Myers Squibb
	15	Rational design, synthesis, and serine protease inhibitory activity of a novel P1-argininal derivative featuring a conformationally constrained P2–P3 bicyclic lactam moiety	TBA
	37	Synthesis and biological activity of P2–P4 azapeptidomimetic P1-argininal and P1-ketoargininamide derivatives: a novel class of serine protease inhibitors	TBA
	25	Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates	TBA
	78	Synthesis and evaluation of 2-aryl-4H-3,1-benzoxazin-4-ones as C1r serine protease inhibitors	TBA
	61	(N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors	TBA
	13	Characterization of LY806303 as a potent and selective inhibitor of thrombin	TBA
19297158	30	Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.	Millennium Pharmaceuticals
19297154	88	Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.	Millennium Pharmaceuticals
19250826	100	Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.	The Medicines Company (Leipzig)
19128974	28	Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.	Daiichi Sankyo
19036586	128	Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors.	Curacyte Discovery
18507371	24	Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.	Takeda Pharmaceutical
17935298	3	Planktocyclin, a cyclooctapeptide protease inhibitor produced by the freshwater cyanobacterium Planktothrix rubescens.	University of ZüRich
17643988	92	Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.	Bristol-Myers Squibb
17420122	18	Selective and dual action orally active inhibitors of thrombin and factor Xa.	Glaxosmithkline
16970403	74	Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.	University of Antwerp
16725321	13	Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.	Celera Genomics
16540315	23	Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.	Mochida Pharmaceutical
16460935	39	A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.	Johnson & Johnson Pharmaceutical Research and Development
16213711	37	Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15801822	28	9-hydroxyazafluorenes and their use in thrombin inhibitors.	Merck Research Laboratories
15582418	103	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.	Abbott Laboratories
15341970	59	P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
15149680	58	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.	Pfizer
15149645	92	Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.	Abbott Laboratories
15115382	16	Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.	University of Antwerp
15013007	319	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.	Millennium Pharmaceuticals
14711304	117	Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.	Abbott Laboratories
14698147	60	Synthesis of potent and selective 2-azepanone inhibitors of human tryptase.	The Bristol-Myers Squibb Pharmaceutical Research Institute
12824021	39	Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.	Boehringer Ingelheim Pharma
12824020	31	Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives.	Boehringer Ingelheim Pharma
12668020	29	Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors.	3-Dimensional Pharmaceuticals
12639567	135	Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.	Millennium Pharmaceuticals
12372529	21	Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity.	Bristol-Myers Squibb Pharmaceutical Research Institute
12113833	183	4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.	Celera
12113832	120	2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.	Celera
12039584	59	Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.	Millennium Pharmaceuticals
12039583	140	Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.	Millennium Pharmaceuticals
11960487	30	Structure-based design of novel potent nonpeptide thrombin inhibitors.	Boehringer Ingelheim Pharma
11958994	31	Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors.	Aventis Pharmaceuticals
11844691	107	4-amidinobenzylamine-based inhibitors of urokinase.	Universitat Jena
11755350	31	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-Substituted-5-halo-2-pyridinyl)guanidines.	Pfizer
11755349	24	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines.	Pfizer
11677132	65	Design, synthesis, and SAR of amino acid derivatives as factor Xa inhibitors.	Cor Therapeutics
11527709	19	Optimization of a screening lead for factor VIIa/TF.	Axys Pharmaceuticals
11495587	198	Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.	Axys Pharmaceuticals
11459634	94	Development of potent and selective factor Xa inhibitors.	Axys Pharmaceuticals
11425539	23	Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones.	Shionogi
11425524	62	Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.	Axys Pharmaceuticals
11378359	57	Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors.	3-Dimensional Pharmaceuticals
32551603	185	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.	Novartis Institutes For Biomedical Research
32456431	24	Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.	Bristol Myers Squibb
32150407	27	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.	Qpex Biopharma
11206478	18	Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.	Institute of Molecular and Cell Biology
11078187	36	Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.	Shionogi
11063603	53	Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.	Pfizer
11055356	236	Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.	Axys Pharmaceuticals
11055355	72	Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.	Axys Pharmaceuticals
11055344	37	Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic P1-ketoamide moieties.	Corvas International
11012033	8	Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines.	Kobe Gakuin University
10937736	35	Nonbenzamidine compounds as selective factor Xa inhibitors.	Aventis Pharmaceuticals
10915052	20	The design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors.	Novartis Horsham Research Centre
27434175	54	Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold.	The University of Queensland
10853674	32	Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors.	Corvas International
27347787	32	Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low Bioavailability.	Astrazeneca
27280436	304	Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines.	Philipps University Marburg
10782677	73	Guanylpiperidine peptidomimetics: potent and selective bis-cation inhibitors of factor Xa.	Corvas International
30707839	63	Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.	Chinese Academy of Sciences
10698439	68	Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.	Rhone-Poulenc Rorer
31679971	44	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.	University of Wollongong
10617091	73	Exploratory solid-phase synthesis of factor Xa inhibitors: discovery and application of p3-heterocyclic amides as novel types of non-basic arginine surrogates.	Corvas International
10560742	85	3-Amidinophenylalanine-based inhibitors of urokinase.	UniversitäT Jena
10509929	116	Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors.	RhôNe-Poulenc Rorer
10508448	11	Combinatorial library of serine and cysteine protease inhibitors that interact with both the S and S' binding sites.	Brown University
10498211	42	Novel benzo-fused lactam scaffolds as factor Xa inhibitors.	Corvas International
31445854	43	Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.	Bristol-Myers Squibb
10425106	12	4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.	Brown University
10328293	23	The discovery of orally available thrombin inhibitors: optimisation of the P1 pharmacophore.	Novartis Horsham Research Centre
10230630	36	Thrombin inhibitors based on a propargylglycine template.	Biotech Research Institute
10206557	36	Investigation of the S3 site of thrombin: design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating P1-argininals.	Corvas International
30520638	54	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma.	The University of Queensland
9873692	54	Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.	Dupont Pharmaceuticals
9873569	16	Design and construction of novel thrombin inhibitors featuring P3-P4 quaternary lactam dipeptide surrogates.	Corvas International
9873397	37	In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors.	3-Dimensional Pharmaceuticals
31833761	32	Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.	Bristol-Myers Squibb
31658420	98	Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.	Philipps University Marburg
9871573	15	Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.	Biotech Research Institute
9822554	14	1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.	Bristol-Myers Squibb Pharmaceutical Research Institute
9784099	84	Design of benzamidine-type inhibitors of factor Xa.	Institut FüR Biochemie
9703466	35	Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.	Merck Research Laboratories
30613336	32	Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.	The University of Queensland
9171866	12	Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.	Merck Research Laboratories
27009905	22	Plasmin inhibitors with hydrophobic amino acid-based linker between hydantoin moiety and benzimidazole scaffold enhance inhibitory activity.	Hiroshima International University
26575094	60	Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.	University of Antwerp (Ua)
26536069	89	Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.	Aarhus University
8426361	111	Highly selective tripeptide thrombin inhibitors.	Eli Lilly
8423602	15	Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series.	Bristol-Myers Squibb Pharmaceutical Research Institute
8035417	23	Retro-binding tripeptide thrombin active-site inhibitors: discovery, synthesis, and molecular modeling.	Bristol-Myers Squibb Pharmaceutical Research Institute
7739010	118	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.	Thrombosis Research Institute
7473571	90	Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions.	Eli Lilly
9722497	2	Aeruginosin 103-A, a thrombin inhibitor from the cyanobacterium Microcystis viridis.	The University of Tokyo
9644086	1	Dehydroradiosumin, a trypsin inhibitor from the cyanobacterium Anabaena cylindrica.	The University of Tokyo
6219223	94	Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin.	TBA
11170666	6	Isolation and structure determination of nostocyclopeptides A1 and A2 from the terrestrial cyanobacterium Nostoc sp. ATCC53789.	University of Hawaii At Manoa
30201291	27	Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.	Abdulaziz University For Health Sciences
29072911	16	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.	University of Nottingham
29501396	59	Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.	Bristol-Myers Squibb
30130401	71	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.	University of Wollongong
28045523	35	Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold.	The University of Queensland
27976897	39	Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics.	Virginia Commonwealth University
29517911	87	Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.	Bicycle Therapeutics
29077405	63	Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).	Bristol-Myers Squibb
1447734	29	Effect of conformational mobility and hydrogen-bonding interactions on the selectivity of some guanidinoaryl-substituted mechanism-based inhibitors of trypsin-like serine proteases.	University of Illinois
28460818	29	Neutral macrocyclic factor VIIa inhibitors.	Bristol-Myers Squibb Research and Development
	18	Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazoles	Hacettepe University
9802391	31	The cloned guinea pig pancreatic polypeptide receptor Y4 resembles more the human Y4 than does the rat Y4.	Uppsala University
24058293	12	Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors.	Durham University